IRIDEX Corporation (IRIX)
NASDAQ: IRIX · Real-Time Price · USD
0.9400
0.00 (0.00%)
Nov 21, 2025, 4:00 PM EST - Market closed
IRIDEX Revenue
IRIDEX had revenue of $12.48M in the quarter ending September 27, 2025, with 7.80% growth. This brings the company's revenue in the last twelve months to $50.65M, up 4.58% year-over-year. In the year 2024, IRIDEX had annual revenue of $48.67M, down -6.17%.
Revenue (ttm)
$50.65M
Revenue Growth
+4.58%
P/S Ratio
0.31
Revenue / Employee
$544,591
Employees
93
Market Cap
16.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2024 | 48.67M | -3.20M | -6.17% |
| Dec 30, 2023 | 51.87M | -5.10M | -8.96% |
| Dec 31, 2022 | 56.97M | 3.07M | 5.69% |
| Jan 1, 2022 | 53.90M | 17.56M | 48.30% |
| Jan 2, 2021 | 36.35M | -7.10M | -16.34% |
| Dec 28, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 29, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 2, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IRIX News
- 9 days ago - IRIDEX Corporation (IRIX) Q3 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 10 days ago - Iridex Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 24 days ago - Iridex to Report Third Quarter 2025 Financial Results on November 11, 2025 - GlobeNewsWire
- 2 months ago - Iridex Corporation Receives Formal Notification of Nasdaq Listing Compliance - GlobeNewsWire
- 3 months ago - IRIDEX Corporation (IRIX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Iridex Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Iridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular Edema - GlobeNewsWire
- 6 months ago - IRIDEX Corporation, Inc. (IRIX) Q1 2025 Earnings Call Transcript - Seeking Alpha